Congress Materials – Psych Congress 2024
Psych Congress 2024 | Oct 29-Nov 2 | Boston, MA
Adjunctive Lumateperone in Patients With Major Depressive Disorder: Results From an Additional Randomized, Double-Blind, Phase 3 Trial
Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Yifan Mo, Hassan Lakkis, John B. Edwards, Susan G. Kornstein, Maurizio Fava
Adjunctive Treatment With Seltorexant Improved Patient-Reported Depressive Symptoms, Insomnia Symptoms, and Overall Health in Major Depressive Disorder With Insomnia
Katherine B. Bevans, Thomas Laughren, Joseph M. Trombello, Ryan Kelly, Yun Zhang, Haiyan Xu, John Thipphawong, Sandra Ruschel, Yanina Flossbach, Carla M. Canuso, Andrew D. Krystal, Wayne C. Drevets, Gahan Pandina
Association of Relapse With All-Cause Mortality in 32,071 Adults With Stable Schizophrenia: A Longitudinal Commercial and Medicare Database Study
Christoph U. Correll, Brahim K. Bookhart, Carmela Benson, Zhiwen Liu, Zhongyun Zhao, Wenze Tang
Burden of Prominent Anhedonia in Major Depressive Disorder Reflected in Polypharmacy, Healthcare Use, and Humanistic Outcomes
Hrishikesh Kale, Michael L. Ganz, Rajrupa Ghosh, Cynthia Saiontz-Martinez, Tiina Drissen, Andrew J. Cutler
Characteristics and Antipsychotic Treatment Pathways of Patients With Schizophrenia Who Received Once-Every-6-Months Paliperidone Palmitate Within the First 2 Years of Approval
Charmi Patel, Dominic Pilon, Laura Morrison, Arthur Voegel, Lilian Diaz, Marie-Hélène Lafeuille, Carmela Benson, Leslie Citrome
Clinical Burden and Treatment Satisfaction in a Real-World Survey of Patients with Major Depressive Disorder with Prominent Anhedonia
Hrishikesh Kale, Jason Shepherd, Nilanjana Dwibedi, Tiina Drissen, Nikisha Grant, Ashley Mortimer, Sophie Kirkman, Sarah Weatherby, Chloe Middleton-Dalby
Clinical Burden of Patients Diagnosed with Major Depressive Disorder with versus without Prominent Anhedonia Using a Real-World Dataset in the United States
Hrishikesh Kale, Geoff Severtson, Becca S. Feldman, Tiina Drissen, Nilanjana Dwibedi, Andrew J. Cutler, Carl D. Marci
Clinical Effectiveness and Persistence on Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Overall and TMS-Naive Subgroup
Tobias Marton, Kruti Joshi, Maryia Zhdanava, Aditi Shah, Dominic Pilon, Bronwyn Moore, Fengyi Jiang, Jennifer Guo
Comparison of Real-World Response and Remission Among Patients With Treatment-Resistant Depression Treated With Esketamine Nasal Spray or Antipsychotic Augmentation
Kristin Clemens, Maryia Zhdanava, Yuxian Du, Arthur Voegel, Anabelle Tardif-Samson, Fengyi Jiang, Dominic Pilon, Kruti Joshi
Disease Burden Associated with Prominent Anhedonia in Patients with Major Depressive Disorder from Adelphi Depression Disease Specific ProgrammeTM
Hrishikesh Kale, Jason Shepherd, Nilanjana Dwibedi, Tiina Drissen, Nikisha Grant, Ashley Mortimer, Sophie Kirkman, Chloe Middleton-Dalby, Sarah Weatherby
Efficacy and Safety of Esketamine Nasal Spray as Monotherapy in Adults with Treatment-Resistant Depression: A Randomized, Double-Blind, Placebo-Controlled Study
Adam Janik, Xin Qiu, Rosanne Lane, Vanina Popova, Wayne C. Drevets, Carla M. Canuso, Dong Jing Fu
Higher Anhedonia is Associated With Poorer Clinical and Humanistic Outcomes Among US Adults With Major Depressive Disorder
Hrishikesh Kale, M. Janelle Cambron-Mellott, Kacper Perkowski, Kristen King-Concialdi, Tiina Drissen, Manish K. Jha
How do Patients with Depression and their Providers Talk about Anhedonia? An Ethnographic Analysis of Healthcare Provider Conversations with Patients in the Clinical Setting
Tiina Drissen, Chelsea McCracken, Hrishikesh Kale, Zachary Hebert, Craig Chepke
Lumateperone Treatment in Patients With Major Depressive Disorder With Mixed Features: Results From a Randomized Controlled Trial
Susan G. Kozauer, Suresh Durgam, Willie R. Earley, Changzheng Chen, Jason Huo, Margaret Martin, Rakesh Jain
Major Depressive Disorder With Clinically Relevant Insomnia Symptoms: Healthcare Professional Assessment of Patient Impact and Clinical Management
Nilanjana Dwibedi, Luis Dieckmann, Peter Falkai, Manish Jha, Sidney Kennedy, Hank Zhang
Pharmacokinetics and Safety of Seltorexant, a Selective Orexin-2 Receptor Antagonist, in Healthy Elderly and Young Non-Asian, and Japanese Adult Participants
Vikash Sinha, Shawn Zhou, Sofie Mesens, Herta Crauwels, Gahan Pandina, Damayanthi Devineni
Real-World Clinical Effectiveness of Esketamine Nasal Spray Based on the Montgomery-Asberg Depression Rating Scale (MADRS) Among Patients With Treatment-Resistant Depression in the United States
Tobias Marton, Kruti Joshi, Maryia Zhdanava, Aditi Shah, Bronwyn Moore, Zhuo Chen, Dominic Pilon, Omar Elhaj
Real-World Comparative Effectiveness of Long-Acting Injectable and Oral Antipsychotics Among US Medicare Beneficiaries With Schizophrenia
Pengxiang Li, Zhi Geng, Carmela Benson, Charmi Patel, Jalpa A. Doshi
Real-World Safety Profile of Esketamine Nasal Spray: An Analysis of the Risk Evaluation and Mitigation Strategy Program Approximately 5 Years After Approval in the United States
Muhammad Ahmed, Mai Himedan, Patricia Cabrera, Ibrahim Turkoz, Brianne Brown, Lisa Lim, Gerard Sanacora
Response and Remission on Esketamine Nasal Spray in Patients With Treatment-Resistant Depression Overall and Among TMS-Naive Subgroup
Tobias Marton, Kruti Joshi, Maryia Zhdanava, Aditi Shah, Dominic Pilon, Bronwyn Moore, Fengyi Jiang, Jennifer Guo
Seltorexant, Adjunctive to Antidepressants, in Adults with MDD with Insomnia Symptoms: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Michael E. Thase, Andrew D. Krystal, Ewa Wajs, Joseph M. Trombello, Ryan Kelly, Yun Zhang, Haiyan Xu, John Thipphawong, Sandra Ruschel, Yanina Flossbach, Gahan Pandina, Carla M. Canuso, Thomas Laughren, Wayne C. Drevets
Symptomatic and Functional Remission with Paliperidone Palmitate 3-month and 6-month Formulations in Adult Patients with Schizophrenia: A 3-Year Analysis
Karen Johnston, James Simples, Ibrahim Turkoz, Lisa Lim, Jose Antunes, Josh Hamilton, Gregory Mattingly, Camilo Obando
Trajectory of Response and Remission in Induction Nonresponders to Esketamine Nasal Spray: A Subgroup Analysis of the SUSTAIN-3 Study
John Zajecka, Naim Zaki, Dong-Jing Fu, Ibrahim Turkoz, Patricia Cabrera, Oliver Lopena, Brianne Brown, Lisa Lim
Treating Insomnia Symptoms as Part of Major Depressive Disorder: A Cross-Sectional Survey on Patient Needs in the US
Zhiheng Zhang, Nilanjana Dwibedi, Jesper Riise, Laury Sellem
Weight and Metabolic Changes in Patients Treated With Esketamine Nasal Spray Versus Quetiapine Extended Release: A Post Hoc Subgroup Analysis of the ESCAPE-TRD Study
Richard Shelton, Clint Mower, Dong-Jing Fu, Ibrahim Turkoz, Patricia Cabrera, Oliver Lopena, Lisa Lim, Larry Martinez
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.